Results 91 to 100 of about 311,632 (269)
Molecular Oncology, EarlyView.This study investigates gene expression differences between two major pediatric acute lymphoblastic leukemia (ALL) subtypes, B‐cell precursor ALL, and T‐cell ALL, using a data‐driven approach consisting of biostatistics and machine learning methods. Following analysis of a discovery dataset, we find a set of 14 expression markers differentiating the ...
Mona Nourbakhsh +8 more
wiley +1 more source
Molecular Oncology, EarlyView.mir‐196a promotes Esophagus Adenocarcinoma aggressiveness. On one hand, mir‐196a targets the valosin‐containing protein (VCP) mRNA, causing the accumulation of c‐MYC protein that leads to high amounts of TERT. On the other hand, mir‐196a targets the inhibitor of NFκB (NFKBIA).
Jesús García‐Castillo +8 more
wiley +1 more source
Multifrequency phase and modulation fluorometry.
Annual Review of Biophysics and Bioengineering, 1984 Ann. Rev. Biophys. Bioeng. 1984. 13: 105-24 MULTIFREQUENCY PHASE AND MODULATION FLUOROMETRY1 Enrico Gratton Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801 David M.
E. Gratton, D. Jameson, R. Hall
semanticscholar +1 more source
TRPM8 levels determine tumor vulnerability to channel agonists
Molecular Oncology, EarlyView.TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo +18 more
wiley +1 more source
Beyond the null: Recognizing and reporting true negative findings
iScienceSummary: Science is based on ideas that might be true or false in describing reality. In order to discern between these two, scientists conduct studies that can reveal evidence for an idea, i.e., positive findings, or not, i.e., negative or null findings.
Manon K. Schweinfurth +1 more
doaj +1 more source
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source
Non-invasive PET imaging of liver fibrogenesis using a RESCA-conjugated Affibody molecule
iScienceSummary: Non-invasive assessment of fibrogenic activity, rather than fibrotic scars, could significantly improve the management of fibrotic diseases and the development of anti-fibrotic drugs.
Olivia Wegrzyniak +12 more
doaj +1 more source
Writing a comprehensive review article in biological sciences, ethnobotany, or pharmacology requires a systematic approach to data collection. This involves defining search strategies, identifying relevant databases, establishing inclusion/exclusion criteria, and assessing study quality. Knowing how to collect data effectively is crucial for producing
openaire +2 more sources
Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma
Molecular Oncology, EarlyView.GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski +19 more
wiley +1 more source
Molecular Oncology, EarlyView.This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau +9 more
wiley +1 more source